Clinical Trial Update: A Study of Carboplatin Plus Etoposide With or Without ZKAB001 (Anti-PD-L1 Antibody) in Patients With ES-SCLC [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating carboplatin and etoposide with or without ZKAB001 (anti-PD-L1) in extensive-stage small-cell lung cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Extensive-stage Small Cell Lung Cancer

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• Etoposide (Etoposide)
• ZKAB001 (PD-L1 antibody)

Snippet

Sponsor: Lee's Pharmaceutical Limited | Conditions: Extensive-stage Small-cell Lung Cancer | Phase 3 | Status: COMPLETED